bullish
Pharmaessentia Corp (6446 TT): Arbitration Reaction Is Overdone; Time to Re-Focus on Fundamentals
393 Views03 Apr 2025 15:14
Pharmaessentia shares plummeted 30% due to ICC ruling, but strong revenue growth and profitability in 2024 set stage for future growth through Besremi expansion and pipeline progress.
What is covered in the Full Insight:
- Introduction
- Arbitration Outcomes
- Financial Performance
- Growth Drivers and Prospects
- Outlook and Valuation
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Related Insights
More »- Pharmaessentia Corp (6446 TT): Strong Start of 2025; Growth Momentum to Continue
- Pharmaessentia Corp (6446 TT): Arbitration Reaction Is Overdone; Time to Re-Focus on Fundamentals
- Pharmaessentia Corp (6446 TT): Third Consecutive Quarters for Operating Profit; Pipeline Raises Hope
- Taiwan Top 50 ETF Rebalance Preview: One Change Right at the Cusp
- Pharmaessentia Corp (6446 TT): Starts 2024 on Strong Note; Reports First Operating Profit in 1Q24
Trending Collections
More »Trending Insights
More »- Nikkei 225 Proposal for Dealing With Sony's (6758) Sony Finl Spinoff - A Non-Event but TOPIX Isn't
- UK: Some Workshy Start Looking
- Index Treatment of Sony (6758 JP)'s Spinoff of the Financial Services Business
- [Japan M&A] Carlyle Deal for TRYT (9164) - Great Exit for Speculators as HR Co Targets Are Desirable
- Samsung Insider’s Flawed Premise on the Samsung C&T Forced Holdco Conversion Issue
Top Unpaywalled Insights
More »- Bearishness Persist in Soybeans Despite Rebound Hopes
- Curator's Cut: The Next Labubu, Crypto Equities and Tracking APAC Buybacks
- [IO Technicals 2025/23] Bearish Momentum Persists
- VEON US: Pakistan Towers Sale Frees Capital for Digital Growth in Core Market Ahead of Ukraine IPO
- Advanced Look: Navigating the New Macro Landscape Through Quantitative Alpha Generation Strategies
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Pharmaessentia Corp (6446 TT): Strong Start of 2025; Growth Momentum to Continue05 Jun 2025
- Pharmaessentia Corp (6446 TT): Arbitration Reaction Is Overdone; Time to Re-Focus on Fundamentals03 Apr 2025
- Pharmaessentia Corp (6446 TT): Third Consecutive Quarters for Operating Profit; Pipeline Raises Hope20 Nov 2024
- Pharmaessentia Corp (6446 TT): Starts 2024 on Strong Note; Reports First Operating Profit in 1Q2425 Jun 2024
- Pharmaessentia Corp (6446 TT): Readying for Next Growth Phase with Besremi’s Continued Traction07 Mar 2024
x